Titan Pharmaceuticals, Inc. (TTNP)

Market Cap	4.96M
Revenue (ttm)	87,000
Net Income (ttm)	-4.95M
Shares Out	914.23K
EPS (ttm)	-6.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	682
Open	5.46
Previous Close	5.54
Day's Range	5.31 - 5.46
52-Week Range	5.00 - 14.00
Beta	1.24
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2024

About TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 18, 1996
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: TTNP

Financial Performance

In 2023, TTNP's revenue was $184,000, a decrease of -66.97% compared to the previous year's $557,000. Losses were -$5.57 million, -45.43% less than in 2022.